These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

706 related articles for article (PubMed ID: 15770489)

  • 21. Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)-a systematic review and individual patient data meta-analysis.
    Chow R; Yin LB; Baqri W; Huang R; Boldt G; Younus J; Lock M; Prsic E; Zimmermann C; Herrstedt J
    Support Care Cancer; 2023 Aug; 31(8):505. PubMed ID: 37535218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy.
    Boccia R; O'Boyle E; Cooper W
    BMC Cancer; 2016 Feb; 16():166. PubMed ID: 26921245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Practices and Outcomes on Chemotherapy-Induced Nausea and Vomiting Management in South Korea: Comparison with Asia-Pacific Data of the Pan Australasian Chemotherapy Induced Emesis Burden of Illness Study.
    Lee MA; Cho EK; Oh SY; Ahn JB; Lee JY; Thomas B; Jung H; Kim JG
    Cancer Res Treat; 2016 Oct; 48(4):1420-1428. PubMed ID: 26875197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance).
    Kottschade L; Novotny P; Lyss A; Mazurczak M; Loprinzi C; Barton D
    Support Care Cancer; 2016 Jun; 24(6):2661-7. PubMed ID: 26768436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy.
    Chasen M; Urban L; Schnadig I; Rapoport B; Powers D; Arora S; Navari R; Schwartzberg L; Gridelli C
    Support Care Cancer; 2017 Jan; 25(1):85-92. PubMed ID: 27557833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin-Based Chemotherapy-Induced Nausea and Vomiting in Japan.
    Iihara H; Shimokawa M; Hayashi T; Kawazoe H; Saeki T; Aiba K; Tamura K
    Oncologist; 2020 Feb; 25(2):e373-e380. PubMed ID: 32043774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of the relationship between adherence with antiemetic drug therapy and control of nausea and vomiting in breast cancer patients receiving anthracycline-based chemotherapy.
    Chan A; Low XH; Yap KY
    J Manag Care Pharm; 2012 Jun; 18(5):385-94. PubMed ID: 22663171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study.
    Molassiotis A; Aapro M; Dicato M; Gascon P; Novoa SA; Isambert N; Burke TA; Gu A; Roila F
    J Pain Symptom Manage; 2014 May; 47(5):839-848.e4. PubMed ID: 24075401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study.
    Navari RM; Einhorn LH; Loehrer PJ; Passik SD; Vinson J; McClean J; Chowhan N; Hanna NH; Johnson CS
    Support Care Cancer; 2007 Nov; 15(11):1285. PubMed ID: 17375339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response.
    Massa E; Astara G; Madeddu C; Dessì M; Loi C; Lepori S; Mantovani G
    Crit Rev Oncol Hematol; 2009 Apr; 70(1):83-91. PubMed ID: 18723369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
    Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
    Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy - a retrospective audit.
    Ng WL; Della-Fiorentina SA
    Eur J Cancer Care (Engl); 2010 May; 19(3):403-7. PubMed ID: 19686353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effectiveness of NEPA in the prevention of chemotherapy-induced nausea vomiting among chemo naive patients in an Indian setting.
    Vaswani B; Dattatreya PS; Bhagat S; Patil S; Barkate H
    BMC Cancer; 2021 May; 21(1):601. PubMed ID: 34034703
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The compliance with antiemetic guidelines of Turkish medical oncologists. A survey study of Turkish Oncology Group.
    Araz M; Karaagac M; Korkmaz L; Beypinar I; Uysal M
    Curr Probl Cancer; 2019 Aug; 43(4):344-353. PubMed ID: 30497851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Delayed nausea and vomiting from carboplatin doublet chemotherapy.
    Waqar SN; Mann J; Baggstrom MQ; Waqar MA; Chitneni P; Williams K; Gao F; Morgensztern D; Govindan R
    Acta Oncol; 2016 Jun; 55(6):700-4. PubMed ID: 27145068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Granisetron Extended-Release Injection: A Review in Chemotherapy-Induced Nausea and Vomiting.
    Deeks ED
    Drugs; 2016 Dec; 76(18):1779-1786. PubMed ID: 27915445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting.
    Burke TA; Wisniewski T; Ernst FR
    Support Care Cancer; 2011 Jan; 19(1):131-40. PubMed ID: 20101417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
    Natale JJ
    Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Palonosetron versus other 5-HT₃ receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies treated with emetogenic chemotherapy in a hospital outpatient setting in the United States.
    Craver C; Gayle J; Balu S; Buchner D
    J Med Econ; 2011; 14(3):341-9. PubMed ID: 21542674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly/Moderately Emetogenic Chemotherapy.
    Hu Z; Liang W; Yang Y; Keefe D; Ma Y; Zhao Y; Xue C; Huang Y; Zhao H; Chen L; Chan A; Zhang L
    Medicine (Baltimore); 2016 Jan; 95(2):e2476. PubMed ID: 26765450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.